Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Asset Writedowns and Impairment (2023 - 2025)

Century Therapeutics (IPSC) has disclosed Asset Writedowns and Impairment for 3 consecutive years, with $6.8 million as the latest value for Q3 2025.

  • Quarterly Asset Writedowns and Impairment changed N/A to $6.8 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $11.1 million through Sep 2025, down 8.69% year-over-year, with the annual reading at $6.8 million for FY2025, 56.3% up from the prior year.
  • Asset Writedowns and Impairment for Q3 2025 was $6.8 million at Century Therapeutics, up from $4.3 million in the prior quarter.
  • The five-year high for Asset Writedowns and Impairment was $12.1 million in Q4 2023, with the low at $4.2 million in Q2 2023.
  • Average Asset Writedowns and Impairment over 3 years is $6.9 million, with a median of $5.5 million recorded in 2024.
  • Peak annual rise in Asset Writedowns and Impairment hit 64.37% in 2024, while the deepest fall reached 64.37% in 2024.
  • Over 3 years, Asset Writedowns and Impairment stood at $12.1 million in 2023, then tumbled by 64.37% to $4.3 million in 2024, then soared by 56.3% to $6.8 million in 2025.
  • According to Business Quant data, Asset Writedowns and Impairment over the past three periods came in at $6.8 million, $4.3 million, and $12.1 million for Q3 2025, Q4 2024, and Q4 2023 respectively.